P679 Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.